As Actos Bladder Cancer Lawsuits Mount, New Study Links Diabetes Drugs to Pancreatic Cancer Risk


Due to its association with an increased risk for bladder cancer, the diabetes drug Actos is the focus of an increasing number of lawsuits against pharmaceutical giant Takeda. Now, a new study indicates other types of diabetes medications may be linked to a heightened risk for pancreatic cancer.

The study, which was published in the January issue of The American Journal of Gastroenterology, found that the diabetes drug Metformin was actually associated with fewer instances of pancreatic cancer in women but that other treatments for type 2 diabetes, including insulin and Sulfonylureas, may actually increase the risk for pancreatic cancer.

Pancreatic cancer spreads quickly and is often deadly. The National Cancer Institute estimates that approximately 44,000 people in the United States will be diagnosed with pancreatic cancer this year and nearly 38,000 will die from the disease.

While Metformin, which is one of the oldest diabetes medications, causes the body to produce or absorb less glucose, insulin and Sulfonylureas stimulate the body to produce more natural insulin in order to help balance blood-sugar levels. Researchers believe the link between insulin and Sulfonylureas and pancreatic cancer may be related to two factors.

First, insulin and Sulfonylureas work directly with the pancreas, one of the primary functions of which is the production of insulin. Second, some previous research has connected highly elevated insulin levels to a greater risk for cancer.

If you developed bladder cancer after taking Actos, an experienced product liability attorney may be able to help you pursue financial compensation for medical expenses, lost wages, and pain and suffering.

Please contact for a free case review and to locate a lawyer near you who specializes in cases related to dangerous pharmaceuticals.